PRODUCTS

BD MAX™ System

Now available

SARS-CoV-2 on the BD MAX™ System

Meet the BD MAX™ System

Efficiency

Workflow efficiency for timely patient management1

  • Run 1-24 samples and/or assays at the same time1,2
  • Increase staff productivity through automation2,3
  • Reduce total costs with increased testing volume and streamlined workflow2
  • Fully automated testing for IVD and open-system reagent capabilities2,4
Efficiency

Performance

Diagnostic speed and accuracy1

  • Molecular testing drives fast, appropriate treatment leading to more timely patient management
  • Timely results allow for prompt infection control and efficient use of isolation resources
Less than 1.5 minutes
Less than 1.5 minutes
hands-on time per specimen2
15 minutes
15 minutes
hands-on time per run2,5
3 hours or less*
3 hours or less*
sample-to-answer for up to 24 specimens2,6

*MDR-TB assay is <4 hours

Versatility

Testing versatility for a wide range of patients2

  • Leverage a broad suite of molecular solutions
  • Address complex patient needs with a clinically relevant and differentiated menu
  • Test up to 24 different samples and/or assays across a wide range of sample types2,4
Up to 24
Up to 24
Samples per run
Mix and match different assays* on the same run

*Assays have defined compatibility and most assays can be put in the same rack. User-defined protocols cannot be in the same rack as IVD assays

Efficiency
Performance
Versatility
Contact us
   

Discover the BD MAX™ System Assays

BD MAX™ System specs

CPO, Carbapenemase-Producing Organism; CT, Chlamydia trachomatis; DNA, deoxyribonucleic acid; GC, Neisseria gonorrhoeae; IVD, in vitro diagnostic; MDR, Multi-Drug Resistant; MRSA, Methicillin-Resistant Staphylococcus aureus; PCR, polymerase chain reaction; RSV, respiratory syncytial virus;  SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TB, Tuberculosis; TNA, total nucleic acid; TV, Trichomonas vaginalis; 

 

1. Mortensen JE et al. BMC Clinical Pathology 2015;15:9. 2.Felder RA et al. J Lab Autom. 2014;19(5):468-473. 3. Le Blanc L et al. Cost-effectiveness and laboratory workload efficiency of 8 C. difficile testing algorithms. Poster presented at: American Society for Microbiology; May 30–June 2, 2015; New Orleans, LA. 4. Bauman M. Transitioning from culture to molecular: implementation and integration of BD MAX™ Enteric Bacterial Panel at Cincinnati Children’s Hospital. BD Advertorial. Franklin Lakes, NJ: Becton, Dickinson and Company; 2015. 5. Hirvonen JJ et al. Eur J Clin Microbiol Infect Dis. 2015;34(5):1005-1009. 6. BD MAX™Enteric Bacterial Panel [package insert]. Becton, Dickinson and Company.